Journal
Nature Communications
DOI
10.1038/s41467-023-39817-3
Method of Research
Experimental study
Subject of Research
Not applicable
Article Title
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
Article Publication Date
20-Jul-2023
COI Statement
MH, TS, MM (Mehling), MS (Selle), RD, BW and JW are inventors on patents related to GDF-15 as a biomarker and therapeutic target. MH, TS and JW are co-founders of the biotech company CatalYm GmbH involved in translating GDF-15-based cancer therapies and diagnostics into the clinics. MH, TS, MR, EL and CSW are current or former employees and stock owners of CatalYm. NV, SG, MCG, KE and PRR are current or former employees of CatalYm. RR is a partner of Forbion Capital partners who are invested in CatalYm. RD has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp
& Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA and touchIME outside the submitted work. AB is scientific cofounder and advisor of Aamuthera Biotech GmbH and DualYX NV that are not related to this work. KWH, HH, FN, RD and JW have received research funding via Catalym GmbH.
Other authors declare no competing interests in this work.
